<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20250109091012&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;ff=20250109091012&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 09 Jan 2025 14:10:12 +0000</lastbuilddate>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Impact of Heart Transplant Allocation Changes on Waitlist Mortality and Clinical Practice in Pediatric and Adult Patients With Congenital Heart Disease and Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39781913/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The recent allocation changes of the Organ Procurement and Transplantation Network associations with waitlist duration and outcome were not uniform across pediatric and adult cohorts with CHD or those with cardiomyopathy. Children with cardiomyopathy and adults with CHD did not experience the mortality benefits experienced by adults with cardiomyopathy and children with CHD. Future iterations of the allocation systems should consider differential access to mechanical circulatory...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 9. doi: 10.1161/CIRCULATIONAHA.124.072335. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The United Network of Organ Sharing made changes to the priority for allocation of hearts for transplantation (HT) in 2016 for pediatric patients and 2018 for adult patients. Although recent work has evaluated the impact of the revised allocation systems on mechanical circulatory support practices and waitlist outcomes, there are limited data that focus more specifically on the impact of the allocation changes on patients with congenital heart disease (CHD) or cardiomyopathy and how these relationships might differ in pediatric and adult patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The United Network of Organ Sharing database was queried for pediatric (&lt;18 years of age) and adult (18-50 years of age) patients with a CHD or cardiomyopathy diagnosis listed for HT. Cohorts were grouped into preallocation and postallocation change eras: pediatric patients from January 1, 2011, to March 21, 2016, and January 1, 2017, to December 31, 2021; and adult patients from January 1, 2015, to October 17, 2018, and January 1, 2019, to December 31, 2021. Differences in era for survival or waitlist removal because of clinical deterioration from the time of HT listing were compared using competing risk models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified 11 637 patients listed for HT during the study period, including 2882 pediatric patients with CHD, 594 adults with CHD, 2348 pediatric patients with cardiomyopathy, and 5813 adults with cardiomyopathy. In a competing risk model adjusting for demographic and clinical factors, allocation changes were significantly associated with lower death or waitlist removal within 1 year of HT listing in infants with CHD (HR, 0.75 [0.57-0.99]; <i>P</i>=0.04), children with CHD (HR, 0.61 [0.43-0.86]; <i>P</i>=0.005), and adults with cardiomyopathy (HR, 0.60 [0.44-0.81]; <i>P</i>=0.001), but not in infants with cardiomyopathy, children with cardiomyopathy, or adults with CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The recent allocation changes of the Organ Procurement and Transplantation Network associations with waitlist duration and outcome were not uniform across pediatric and adult cohorts with CHD or those with cardiomyopathy. Children with cardiomyopathy and adults with CHD did not experience the mortality benefits experienced by adults with cardiomyopathy and children with CHD. Future iterations of the allocation systems should consider differential access to mechanical circulatory support options for children and adults, patient sensitization status, and whether having separate systems for adults and children is the most appropriate method to allocate organs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39781913/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39781913</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072335>10.1161/CIRCULATIONAHA.124.072335</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39781913</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Luke Wooster</dc:creator>
<dc:creator>Matthew J O'Connor</dc:creator>
<dc:creator>Xuemei Zhang</dc:creator>
<dc:creator>Constantine D Mavroudis</dc:creator>
<dc:creator>Katsuhide Maeda</dc:creator>
<dc:creator>Humera Ahmed</dc:creator>
<dc:creator>Jonathan Edwards</dc:creator>
<dc:creator>Kimberly Y Lin</dc:creator>
<dc:creator>Carol Wittlieb-Weber</dc:creator>
<dc:creator>Joseph Rossano</dc:creator>
<dc:creator>Jonathan B Edelson</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Heart Transplant Allocation Changes on Waitlist Mortality and Clinical Practice in Pediatric and Adult Patients With Congenital Heart Disease and Cardiomyopathy</dc:title>
<dc:identifier>pmid:39781913</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072335</dc:identifier>
</item>
<item>
<title>Prevalence and Clinical Outcomes of Discordant Lesions Between Fractional Flow Reserve and Nonhyperemic Pressure Ratios in Clinical Practice: The J-PRIDE Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39781739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Discordance between FFR and NHPRs was noted in 20% of lesions, and discordant deferred lesions resulted in worse outcomes than concordant negative lesions. Although the outcomes after deferring revascularization were comparable between the FFR+/NHPR- and FFR-/NHPR+ lesions, only FFR+/NHPR- lesions showed a benefit from revascularization compared with medical treatment, suggesting that an FFR-guided strategy is superior to an NHPR-guided strategy in discordant lesions.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 9. doi: 10.1161/CIRCULATIONAHA.124.071139. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited large-scale, real-world data exist on the prevalence and clinical impact of discordance between fractional flow reserve (FFR) and nonhyperemic pressure ratios (NHPRs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The J-PRIDE registry (Clinical Outcomes of Japanese Patients With Coronary Artery Disease Assessed by Resting Indices and Fractional Flow Reserve: A Prospective Multicenter Registry) prospectively enrolled 4304 lesions in 3200 patients from 20 Japanese centers. The lesions were classified into FFR+/NHPR-, FFR-/NHPR+, FFR+/NHPR+, or FFR-/NHPR groups according to cutoff values of 0.89 for NHPRs and 0.80 for FFR. The primary study end point was the cumulative 1-year incidence of target vessel failure (a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization) on a lesion basis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: An NHPR cutoff value of 0.89, determined using online software, predicted an FFR of 0.80 across various NHPR types. Discordance between FFR and NHPRs was observed in 20% of lesions (FFR+/NHPR-, 11.2%; FFR-/NHPRs+, 8.8%). Revascularization was deferred in 42.9% and 88.4% of the FFR+/NHPR- and FFR-/NHPR+ groups, respectively. In deferred vessels, the FFR+/NHPR- and FFR-/NHPR+ groups showed a higher 1-year incidence of target vessel failure compared with the FFR-/NHPR- group (7.9% versus 5.5% versus 1.7%; for FFR+/NHPR-, adjusted hazard ratio [aHR], 4.89 [95% CI, 2.68-8.91]; <i>P</i>&lt;0.001; for FFR-/NHPR+, aHR, 2.64 [95% CI, 1.49-4.69]; <i>P</i>&lt;0.001). In revascularized vessels, the 1-year target vessel failure rate was numerically higher in the FFR-/NHPR+ group than in the FFR+/NHPR+ group (9.6% versus 3.4%; aHR, 2.27 [95% CI, 0.70-7.34]; <i>P</i>=0.17), although with similar outcomes between the FFR+/NHPR- and FFR+/NHPR+ groups (2.3% versus 3.4%; aHR, 0.96 [95% CI, 0.37-2.38]; <i>P</i>=0.93). The FFR+/NHPR- group benefited from revascularization compared with medical treatment (aHR, 0.26 [95% CI, 0.08-0.86]; <i>P</i>=0.027); the FFR-/NHPR+ group did not (aHR, 2.39 [95% CI, 0.62-9.21]; <i>P</i>=0.20).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Discordance between FFR and NHPRs was noted in 20% of lesions, and discordant deferred lesions resulted in worse outcomes than concordant negative lesions. Although the outcomes after deferring revascularization were comparable between the FFR+/NHPR- and FFR-/NHPR+ lesions, only FFR+/NHPR- lesions showed a benefit from revascularization compared with medical treatment, suggesting that an FFR-guided strategy is superior to an NHPR-guided strategy in discordant lesions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.umin.ac.jp; Unique identifier: UMIN000038403.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39781739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39781739</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071139>10.1161/CIRCULATIONAHA.124.071139</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39781739</guid>
<pubDate>Thu, 09 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shoichi Kuramitsu</dc:creator>
<dc:creator>Yoshiaki Kawase</dc:creator>
<dc:creator>Tomohiro Shinozaki</dc:creator>
<dc:creator>Takenori Domei</dc:creator>
<dc:creator>Futoshi Yamanaka</dc:creator>
<dc:creator>Umihiko Kaneko</dc:creator>
<dc:creator>Tsunekazu Kakuta</dc:creator>
<dc:creator>Kazunori Horie</dc:creator>
<dc:creator>Hidenobu Terai</dc:creator>
<dc:creator>Hirohiko Ando</dc:creator>
<dc:creator>Yasutsugu Shiono</dc:creator>
<dc:creator>Toru Tagashira</dc:creator>
<dc:creator>Kazutaka Nogi</dc:creator>
<dc:creator>Takashi Kubo</dc:creator>
<dc:creator>Taku Asano</dc:creator>
<dc:creator>Jun Shiraishi</dc:creator>
<dc:creator>Hiromasa Otake</dc:creator>
<dc:creator>Akinori Sugano</dc:creator>
<dc:creator>Reo Anai</dc:creator>
<dc:creator>Atsushi Iwai</dc:creator>
<dc:creator>Yuetsu Kikuta</dc:creator>
<dc:creator>Hidetaka Nishina</dc:creator>
<dc:creator>Tsutomu Fujita</dc:creator>
<dc:creator>Tetsuya Amano</dc:creator>
<dc:creator>Masashi Iwabuchi</dc:creator>
<dc:creator>Hiroyoshi Yokoi</dc:creator>
<dc:creator>Takashi Akasaka</dc:creator>
<dc:creator>Hitoshi Matsuo</dc:creator>
<dc:creator>Nobuhiro Tanaka</dc:creator>
<dc:creator>J-PRIDE Investigators</dc:creator>
<dc:date>2025-01-09</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prevalence and Clinical Outcomes of Discordant Lesions Between Fractional Flow Reserve and Nonhyperemic Pressure Ratios in Clinical Practice: The J-PRIDE Registry</dc:title>
<dc:identifier>pmid:39781739</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071139</dc:identifier>
</item>
<item>
<title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e9. doi: 10.1016/j.jacc.2024.10.116.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779064</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.116>10.1016/j.jacc.2024.10.116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779064</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Suvasini Lakshmanan</dc:creator>
<dc:creator>Venkat Sanjay Manubolu</dc:creator>
<dc:creator>Matthew J Budoff</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779064</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.116</dc:identifier>
</item>
<item>
<title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e7. doi: 10.1016/j.jacc.2024.08.088.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779063/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779063</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.088>10.1016/j.jacc.2024.08.088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779063</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gianluca Iacobellis</dc:creator>
<dc:creator>Alexis Elias Malavazos</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>How Semaglutide Effects on Epicardial Fat Inflammation Can Be Good for the Heart</dc:title>
<dc:identifier>pmid:39779063</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.088</dc:identifier>
</item>
<item>
<title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e17. doi: 10.1016/j.jacc.2024.10.115.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779062/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779062</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.115>10.1016/j.jacc.2024.10.115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779062</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sahmin Lee</dc:creator>
<dc:creator>Jae-Kwan Song</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779062</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.115</dc:identifier>
</item>
<item>
<title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e15. doi: 10.1016/j.jacc.2024.09.1243.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779061/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779061</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1243>10.1016/j.jacc.2024.09.1243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779061</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jonathan L Ciofani</dc:creator>
<dc:creator>Ravinay Bhindi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Timing of Medical Therapy for Aortic Stenosis: Too Little Too Late?</dc:title>
<dc:identifier>pmid:39779061</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1243</dc:identifier>
</item>
<item>
<title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e13. doi: 10.1016/j.jacc.2024.09.1242.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779060/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779060</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1242>10.1016/j.jacc.2024.09.1242</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779060</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rodney H Falk</dc:creator>
<dc:creator>Sarah A M Cuddy</dc:creator>
<dc:creator>Osnat Itzhaki Ben Zadok</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779060</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1242</dc:identifier>
</item>
<item>
<title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):e11-e12. doi: 10.1016/j.jacc.2024.08.087.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779059/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779059</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.087>10.1016/j.jacc.2024.08.087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779059</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Giuseppe Vergaro</dc:creator>
<dc:creator>Giorgia Panichella</dc:creator>
<dc:creator>Vincenzo Castiglione</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It?</dc:title>
<dc:identifier>pmid:39779059</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.087</dc:identifier>
</item>
<item>
<title>Introducing Brief Features in JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779058/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):86-87. doi: 10.1016/j.jacc.2024.12.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779058/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779058</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.001>10.1016/j.jacc.2024.12.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779058</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Introducing Brief Features in JACC</dc:title>
<dc:identifier>pmid:39779058</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.001</dc:identifier>
</item>
<item>
<title>Prostanoids and Heart Failure: Friend or Foe?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):71-73. doi: 10.1016/j.jacc.2024.11.016.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779057</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.016>10.1016/j.jacc.2024.11.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779057</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prostanoids and Heart Failure: Friend or Foe?</dc:title>
<dc:identifier>pmid:39779057</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.016</dc:identifier>
</item>
<item>
<title>Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779056/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Systemic thromboxane A(2) generation as measured by urinary TXB(2)-M(GFR) was significantly associated with HF risk and remained so after accounting for traditional risk factors. Urinary TXB(2)-M(GFR) is therefore a potentially useful novel biomarker to identify at-risk individuals who might benefit from aggressive primary prevention.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):58-70. doi: 10.1016/j.jacc.2024.09.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Systemic thromboxane A<sub>2</sub> generation, which is readily assessed by quantifying thromboxane B<sub>2</sub> metabolites (TXB<sub>2</sub>-M) in the urine, is associated with impaired cardiac performance and mortality in aspirin (ASA) users with heart failure (HF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine the association of urinary TXB<sub>2</sub>-M with the risk of developing HF in individuals without prior history of HF and with normal left ventricular function irrespective of ASA use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Urine TXB<sub>2</sub>-M were measured by immunoassay and adjusted to urine concentration and renal function (TXB<sub>2</sub>-M<sub>GFR</sub>) in 2,611 Framingham Heart Study participants (54.9% women, mean age 65 ± 9 years, 43.8% ASA users) without prior history of HF and with left ventricular ejection fraction (LVEF) ≥55%. The association of TXB<sub>2</sub>-M<sub>GFR</sub> with HF risk over a median observation period of 14.8 years (Q1-Q3: 12.6-15.7 years) was modeled using Cox regression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: HF occurred in 189 participants (7.2%), with 104 of the first events (55.0%) classified as HF with preserved LVEF, 56 (29.6%) as HF with reduced LVEF, and 29 (15.3%) were unclassifiable. TXB<sub>2</sub>-M<sub>GFR</sub> levels, above compared to below, of 16.6 and 62.1 filtered prostanoid units for ASA users and nonusers, respectively, were associated with increased risk of developing HF (HR: 1.81; 95% CI: 1.38-2.64; P &lt; 0.0001, adjusted for age, sex, ASA use, and HF risk factors), including both HF subtypes (HF with preserved LVEF: HR: 1.81; 95% CI: 1.17-2.80; P = 0.0081, and HF with reduced LVEF: HR: 2.63; 95% CI: 1.48-4.68; P = 0.0010, adjusted for age, sex, ASA use, and cardiovascular disease). Neither ASA use nor evidence of platelet activation, as measured by plasma P-selectin, were independently associated with HF risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Systemic thromboxane A<sub>2</sub> generation as measured by urinary TXB<sub>2</sub>-M<sub>GFR</sub> was significantly associated with HF risk and remained so after accounting for traditional risk factors. Urinary TXB<sub>2</sub>-M<sub>GFR</sub> is therefore a potentially useful novel biomarker to identify at-risk individuals who might benefit from aggressive primary prevention.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779056/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779056</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.010>10.1016/j.jacc.2024.09.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779056</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jeffrey J Rade</dc:creator>
<dc:creator>Shari S Kronsberg</dc:creator>
<dc:creator>Thomas S Kickler</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Vanessa Xanthakis</dc:creator>
<dc:creator>Matthew G Nayor</dc:creator>
<dc:creator>Bruce A Barton</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure</dc:title>
<dc:identifier>pmid:39779056</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.010</dc:identifier>
</item>
<item>
<title>Complete Revascularization Wins in ST-Segment Elevation Myocardial Infarction, But Timing Remains Flexible</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779055/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):39-41. doi: 10.1016/j.jacc.2024.10.078.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779055/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779055</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.078>10.1016/j.jacc.2024.10.078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779055</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Ori Ben-Yehuda</dc:creator>
<dc:creator>Ehtisham Mahmud</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Complete Revascularization Wins in ST-Segment Elevation Myocardial Infarction, But Timing Remains Flexible</dc:title>
<dc:identifier>pmid:39779055</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.078</dc:identifier>
</item>
<item>
<title>Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39779054/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among patients with STEMI and multivessel disease, outcomes were better with immediate or staged CR compared with culprit vessel-only treatment, whether with angiographic or functional guidance.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 7;85(1):19-38. doi: 10.1016/j.jacc.2024.09.1231.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, most but not all randomized trials have reported that complete revascularization (CR) offers advantages over culprit vessel-only revascularization. In addition, the optimal timing and assessment methods for CR remain undetermined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to identify the optimal revascularization strategy in patients with STEMI and multivessel disease, using a network meta-analysis of randomized controlled trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We searched PUBMED and EMBASE for randomized trials evaluating revascularization strategies in patients with STEMI and multivessel disease through July 2024. A network meta-analysis was performed analyzing CR vs culprit vessel-only revascularization as well as the timing of CR (immediate CR vs staged CR). Outcomes were also assessed with 4 CR strategies based on whether revascularization was immediate or staged and whether it was angiographically guided or functionally guided. The primary outcome was major adverse cardiovascular events (MACE).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 26 randomized trials that enrolled 15,902 patients were included. The mean weighted duration of follow-up was 25.2 ± 15.7 months. MACE was reduced with both immediate CR and staged CR compared with culprit-vessel-only treatment (RR: 0.48; 95% CI: 0.36-0.64 and RR: 0.65; 95% CI: 0.52-0.82, respectively), whether with angiographic or functional guidance. Immediate CR was associated with reduced MACE compared with staged CR (RR: 0.74; 95% CI: 0.56-0.97), whether CR was guided angiographically or functionally (RR: 0.77; 95% CI: 0.61-0.99 and RR: 0.49; 95% CI: 0.27-0.89, respectively) caused by reductions in MI. However, when the analysis was restricted to studies that reported both all MI and nonprocedural MI, the benefit of immediate CR in reducing MI compared with staged CR was diminished after excluding procedural MI (RR: 0.44; 95% CI: 0.27-0.71 with procedural MI vs RR: 0.65; 95% CI: 0.36-1.16 without procedural MI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among patients with STEMI and multivessel disease, outcomes were better with immediate or staged CR compared with culprit vessel-only treatment, whether with angiographic or functional guidance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39779054/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39779054</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1231>10.1016/j.jacc.2024.09.1231</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39779054</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Keitaro Akita</dc:creator>
<dc:creator>Yuko Kiyohara</dc:creator>
<dc:creator>Hisato Takagi</dc:creator>
<dc:creator>Alexandros Briasoulis</dc:creator>
<dc:creator>Jose Wiley</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimal Strategy for Complete Revascularization in ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Network Meta-Analysis</dc:title>
<dc:identifier>pmid:39779054</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1231</dc:identifier>
</item>
<item>
<title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae759. doi: 10.1093/eurheartj/ehae759. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39776179</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae759>10.1093/eurheartj/ehae759</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776179</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Eisuke Kagawa</dc:creator>
<dc:creator>Masaya Kato</dc:creator>
<dc:creator>Keigo Dote</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning for cardiac abnormalities in chest X-rays: performance metrics with imbalanced data and extracardiac objects</dc:title>
<dc:identifier>pmid:39776179</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae759</dc:identifier>
</item>
<item>
<title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae935. doi: 10.1093/eurheartj/ehae935. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39776175</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae935>10.1093/eurheartj/ehae935</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776175</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jacopo Lin</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Michele De Bonis</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Giant left atrial appendage aneurysm: a source of multiple thrombotic events despite medical therapy</dc:title>
<dc:identifier>pmid:39776175</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae935</dc:identifier>
</item>
<item>
<title>Coffee drinking timing and mortality in US adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae871. doi: 10.1093/eurheartj/ehae871. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: To identify the patterns of coffee drinking timing in the US population and evaluate their associations with all-cause and cause-specific mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study included 40 725 adults from the National Health and Nutrition Examination Survey 1999-2018 who had complete information on dietary data and 1463 adults from the Women's and Men's Lifestyle Validation Study who had complete data on 7-day dietary record. Clustering analysis was used to identify patterns of coffee drinking timing.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this observational study, two distinct patterns of coffee drinking timing [morning type (36% of participants) and all-day-type patterns (14% of participants)] were identified in the National Health and Nutrition Examination Survey and were validated in the Women's and Men's Lifestyle Validation Study. During a median (interquartile range) follow-up of 9.8 (9.1) years, a total of 4295 all-cause deaths, 1268 cardiovascular disease deaths, and 934 cancer deaths were recorded. After adjustment for caffeinated and decaffeinated coffee intake amounts, sleep hours, and other confounders, the morning-type pattern, rather than the all-day-type pattern, was significantly associated with lower risks of all-cause (hazard ratio: .84; 95% confidential interval: .74-.95) and cardiovascular disease-specific (hazard ratio: .69; 95% confidential interval: .55-.87) mortality as compared with non-coffee drinking. Coffee drinking timing significantly modified the association between coffee intake amounts and all-cause mortality (P-interaction = .031); higher coffee intake amounts were significantly associated with a lower risk of all-cause mortality in participants with morning-type pattern but not in those with all-day-type pattern.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776171/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39776171</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae871>10.1093/eurheartj/ehae871</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776171</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xuan Wang</dc:creator>
<dc:creator>Hao Ma</dc:creator>
<dc:creator>Qi Sun</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Yoriko Heianza</dc:creator>
<dc:creator>Rob M Van Dam</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Eric Rimm</dc:creator>
<dc:creator>JoAnn E Manson</dc:creator>
<dc:creator>Lu Qi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coffee drinking timing and mortality in US adults</dc:title>
<dc:identifier>pmid:39776171</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae871</dc:identifier>
</item>
<item>
<title>Start your day with a morning coffee!</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae823. doi: 10.1093/eurheartj/ehae823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776142/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39776142</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae823>10.1093/eurheartj/ehae823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776142</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Thomas F Lüscher</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Start your day with a morning coffee!</dc:title>
<dc:identifier>pmid:39776142</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae823</dc:identifier>
</item>
<item>
<title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae900. doi: 10.1093/eurheartj/ehae900. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39776140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39776140</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae900>10.1093/eurheartj/ehae900</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39776140</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yusuke Sato</dc:creator>
<dc:creator>Tetsuji Morishita</dc:creator>
<dc:creator>Hiroshi Tada</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Efficacy of aggressive lipid-lowering therapy on plaque stabilization in femoropopliteal disease, assessed using near-infrared spectroscopy intravascular ultrasound</dc:title>
<dc:identifier>pmid:39776140</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae900</dc:identifier>
</item>
<item>
<title>Combustible cigarette smoking harms nearly every organ in the body</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae896. doi: 10.1093/eurheartj/ehae896. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775792/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39775792</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae896>10.1093/eurheartj/ehae896</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775792</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Combustible cigarette smoking harms nearly every organ in the body</dc:title>
<dc:identifier>pmid:39775792</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae896</dc:identifier>
</item>
<item>
<title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 8:ehae760. doi: 10.1093/eurheartj/ehae760. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775785/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39775785</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae760>10.1093/eurheartj/ehae760</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775785</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Pierre Elias</dc:creator>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Timothy Joseph Poterucha</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Novel technology, novel challenges: How do we compare the performance of artificial intelligence to human experts?</dc:title>
<dc:identifier>pmid:39775785</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae760</dc:identifier>
</item>
<item>
<title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250109091012&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 8. doi: 10.1001/jamacardio.2024.4820. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39775777/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250109091012&v=2.18.0.post9+e462414">39775777</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4820>10.1001/jamacardio.2024.4820</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39775777</guid>
<pubDate>Wed, 08 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2025-01-08</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genius and the CVD Polypill-A Step Toward Achieving Health Equity?</dc:title>
<dc:identifier>pmid:39775777</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4820</dc:identifier>
</item>





























</channel>
</rss>